Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: Results of the international randomized phase III trial (MISTRAL)

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1546-1552

  Betticher, D C ^a,e   Martinelli, G ^b   Radford, J A ^c   Kaufmann, M ^d   Dyer, M J S ^c   Kaiser, U ^d   Aulitzky, W E ^d   Beck, J ^d   von Rohr, A ^a   Kovascovics, T ^a   Cogliatti, S B ^a   Cina, S ^a   Maibach, R ^a   Cerny, T ^a   Linch, D C ^c  

^a SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UKCCCR Lymphoma Subcommittee   (United Kingdom)

^d German Lymphoma Study Group   (Germany)

^e Hopital Cantonal de Fribourg   (Switzerland)

Author keywords

Aggressive lymphoma; Autologus bone marrow transplantation; Diffuse large cell lymphoma; Sequential high dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROCORTISONE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DYSPHAGIA; DYSPNEA; DYSURIA; ESOPHAGITIS; FEMALE; FEVER; GASTRITIS; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERHEMOGLOBINEMIA; INFECTION; INTESTINE PERFORATION; KIDNEY FAILURE; LEUKOPENIA; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHILIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERITONITIS; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; STEM CELL TRANSPLANTATION; STOMACH ULCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 33749649484     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl153     Document Type: Article

References (24)

1. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-1006.
2. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
3. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23(18): 4117-4126.
4. Habermann TM, Weller EA, Morrison VA et al. Phase III trial of tiruximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with DLBL. Blood 2004; 102 Suppl 1: Abstr 6a.
5. Santini G, Salvagno L, Leoni P et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796-2802.
6. Intragumtornchai T, Prayoonwiwat W, Numbenjapon T et al. CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 219-225.
7. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22-30.
8. Haioun C, Lepage E, Gisselbrecht C et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994; 12: 2543-2551.
9. Kaiser U, Uebelacker I, Abel U et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. J Clin Oncol 2002; 20: 4413-4419.
10. Martelli M, Gherlinzoni F, De Renzo A et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255-1262.
11. Olivieri A, Santini G, Patti C et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long-term results by the NHLCSG. Ann Oncol 2005; 16: 1941-1948.
12. Gisselbrecht C, Lepage E, Molina T et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472-2479.
13. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
14. Milpied N, Deconinck E, Gaillard F et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
15. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
16. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
17. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 549-556.
18. O'Brien PC, Fleiming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
19. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
20. Bosly A, Coiffier B, Gisselbrecht C et al. Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen. J Clin Oncol 1992; 10: 1615-1623.
21. Vose JM, Anderson JR, Kessinger A et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851.
22. Kessinger A, Armitage JO, Smith DM et al. High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphoma. Blood 1989; 74: 1260-1265.
23. Haioun C, Lepage E, Gisselbrecht C et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997; 15: 1131-1137.
24. Greb A, Bohlius J, Schwarzer G et al. High-dose chemotherapy with autologous stem cell support does not improve outcome in the first-line treatment of aggressive non-Hodgkin's lymphoma - results of a comprehensive meta-analysis. Ann Oncol 2005; 16: V55 (Abstr. 68).